Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Kallikrein B, Plasma (Fletcher Factor) 1 (KLKB1) Peptide

KLKB1 Reactivity: Human Host: Synthetic BP, WB
Catalog No. ABIN979081

Quick Overview for Kallikrein B, Plasma (Fletcher Factor) 1 (KLKB1) Peptide (ABIN979081)

Target

KLKB1 (Kallikrein B, Plasma (Fletcher Factor) 1 (KLKB1))

Origin

Human

Source

  • 3
Synthetic

Application

Blocking Peptide (BP), Western Blotting (WB)
  • Characteristics

    This is a synthetic peptide designed for use in combination with anti-KLKB1 antibody (Catalog #: ARP45678_T100). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.

    Purification

    Purified
  • Application Notes

    Each Investigator should determine their own optimal working dilution for specific applications.

    Restrictions

    For Research Use only
  • Format

    Lyophilized

    Reconstitution

    Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.

    Concentration

    1 mg/mL

    Buffer

    Final peptide concentration is 1 mg/mL in PBS.

    Handling Advice

    Avoid repeated freeze-thaw cycles.

    Storage

    -20 °C

    Storage Comment

    For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
  • Target

    KLKB1 (Kallikrein B, Plasma (Fletcher Factor) 1 (KLKB1))

    Background

    Plasma prekallikrein is a glycoprotein that participates in the surface-dependent activation of blood coagulation, fibrinolysis, kinin generation and inflammation. It is synthesized in the liver and secreted into the blood as a single polypeptide chain. Plasma prekallikrein is converted to plasma kallikrein by factor XIIa by the cleavage of an internal Arg-Ile bond. Plasma prekallikrein deficiency causes a prolonged activated partial thromboplastin time in patients.Plasma prekallikrein is a glycoprotein that participates in the surface-dependent activation of blood coagulation, fibrinolysis, kinin generation and inflammation. It is synthesized in the liver and secreted into the blood as a single polypeptide chain. Plasma prekallikrein is converted to plasma kallikrein by factor XIIa by the cleavage of an internal Arg-Ile bond. Plasma kallikrein therefore is composed of a heavy chain and a light chain held together by a disulphide bond. The heavy chain originates from the amino-terminal end of the zymogen and contains 4 tandem repeats of 90 or 91 amino acids. Each repeat harbors a novel structure called the apple domain. The heavy chain is required for the surface-dependent pro-coagulant activity of plasma kallikrein. The light chain contains the active site or catalytic domain of the enzyme and is homologous to the trypsin family of serine proteases. Plasma prekallikrein deficiency causes a prolonged activated partial thromboplastin time in patients.

    Alias Symbols: KLK3, PPK

    Protein Interaction Partner: F12,HGF,HGFAC,IGFBP3,KNG1,MST1,SERPINA5,TFPI2,KNG1,SERPINA5

    Protein Size: 638

    Molecular Weight

    28 kDa

    Gene ID

    3818

    NCBI Accession

    NM_000892, NP_000883

    UniProt

    P03952
You are here:
Chat with us!